“…Levels of BP-1 rise severalfold in patients with poorly controlled diabetes, and fall promptly with insulin therapy (Suikkari et al 1988). High molecular-weight (MW) IGF inhibitors appear to lower circulating IGFs bioactivity in diabetes, malnutrition, and steroid excess, while low-MW IGF inhibitors are more important in kidney failure (Phillips et al 1989).…”